


CONCLUSION

Applicants submit that the amendments do not introduce new matter, and respectfully request entry thereof. Upon entry of the amendments, claims 184 and 185 will be pending.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: December 26, 2001

By:


James P. Demers
Registration No. 34,320

CORRESPONDENCE ADDRESS:
MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile

APPENDIX

New claims:

184. (new) A method for members of a business partnership, which comprises at least a first business partner and a second business partner, to determine correlations between haplotypes or haplotype pairs, or both, and clinical responses to a drug or drug candidate, characterized in that:

- (a) the second business partner conveys to the first business partner the identity of one or more candidate genes selected from the group consisting of: genes that encode proteins that are known to play a role in the clinical response of a patient to the drug or drug candidate, and genes that encode proteins that are suspected to play a role in the clinical response of a patient to the drug or drug candidate;
- (b) the second business partner provides to the first business partner samples of genetic material from individual patients within a clinical cohort of patients who have been administered said drug or drug candidate;
- (c) the second business partner conveys to the first business partner data describing individual clinical responses of said individual patients to said drug or drug candidate;
- (d) the first business partner conducts a haplotype analysis of the candidate genes in the samples of genetic material, said analysis including the identification of known haplotypes or haplotype pairs, or both, and optionally including the discovery of new haplotypes;
- (e) the first business partner determines the associations between one or more haplotypes or haplotype pairs, or both, and the clinical responses of the patients in the cohort; and
- (f) the first business partner discloses said associations to the second business partner.

185. (new) A method for members of a business partnership to discover, develop, and deliver pharmaceuticals, characterized in that:

(a) the business partnership comprises at least a first business partner and a second business partner;

(b) the first business partner identifies haplotypes for genes and/or other loci found in a diverse set of individuals and stores the identified haplotypes in a relational database designed for efficiently storing and searching genomic and clinical information;

(c) the first business partner conveys to the second business partner access to an informatics application which comprises the relational database and algorithms designed to find correlations between haplotypes or haplotype pairs, or both, stored in the database and a clinical outcome; and

(d) the second business partner uses the informatics application for one or more research and development activities selected from the group consisting of: target validation, lead prioritization, lead optimization, design of clinical trials, and interpretation of clinical trials.